Search - tctmd.com

Displaying 121 - 140 of 180

Sort: Relevancy | Date

News Daily News

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

L.A. McKeown

April 18, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

Todd Neale

April 17, 2024

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Todd Neale

April 12, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Presentation ACC 2024

PROACT: Can we prevent chemotherapy-related heart damage in patients with breast cancer and lymphoma?

Presenter: David Austin

April 08, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Presentation ACC 2024

Primary Results from the Phase 2 KARDIA-2 Study

Presenter: Akshay Desai

April 07, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

News Conference News ACC 2024

Faster CAC Progression After Menopause May Warrant Intensified Therapy

L.A. McKeown

April 04, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Daily News

Antihypertensives Linked to Lower Long-term Dementia Risk

Caitlin E. Cox

April 01, 2024

News Conference News ACC 2024

ADHD Meds Linked to Cardiomyopathy in Young Adults

Todd Neale

April 01, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Advertisement

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Need a Statin for Primary Prevention? There’s an App for That

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

PROACT: Can we prevent chemotherapy-related heart damage in patients with breast cancer and lymphoma?

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Primary Results from the Phase 2 KARDIA-2 Study

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Faster CAC Progression After Menopause May Warrant Intensified Therapy

April 2024 Dispatch for the CV Team

Antihypertensives Linked to Lower Long-term Dementia Risk

ADHD Meds Linked to Cardiomyopathy in Young Adults

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content